This website uses cookies and other technologies to personalize content and ads on this and other websites and provide social media features. By clicking "I Agree" you consent to our use of tracking technologies and disclosure of tracking data to third party ad networks or social media companies for the purposes above. If you click "I Disagree" you can still use this website. For more information about Lilly’s privacy practice and to manage third-party preferences, click here.

FOR HEALTHCARE PROVIDERS

Emgality is a calcitonin gene-related peptide (CGRP) binding antibody studied in migraine and episodic cluster headache1

Emgality is a humanized monoclonal antibody that binds to CGRP and blocks its binding to the receptor1

CGRP, Emgality, CGRP receptor and blood vessel

There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.1

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Emgality works differently than many other preventive medications because it was specifically developed to bind to CGRP, a substance in the brain that may play a key role in migraine1-3

View real-world refill rate equivalent data for select preventive migraine medications

Reference: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 3. Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat. 2006;2(3):281-291.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 10DEC2019

Are you a US healthcare provider?

The information contained in this section of Emgality.com is intended for US healthcare providers. Please confirm below.

No

You are now leaving Emgality.com.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Click “Continue” to leave site or “Return to Emgality.com” to close this window and return to Emgality.com.

Are you a US healthcare provider?

The information contained in this section of Emgality.com is intended for US healthcare providers. Please confirm below.